BioLineRx Ltd.
BLRX
$3.85
$0.112.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.22% | -97.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.22% | -97.83% | |||
| Cost of Revenue | 111.76% | -99.44% | |||
| Gross Profit | 4.98% | -96.10% | |||
| SG&A Expenses | -78.87% | -85.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.47% | -82.26% | |||
| Operating Income | 3.68% | 24.57% | |||
| Income Before Tax | -176.85% | 260.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -176.85% | 260.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -176.85% | 260.87% | |||
| EBIT | 3.68% | 24.57% | |||
| EBITDA | 4.45% | -15.34% | |||
| EPS Basic | -173.91% | 195.83% | |||
| Normalized Basic EPS | -171.43% | 255.56% | |||
| EPS Diluted | -173.91% | 195.83% | |||
| Normalized Diluted EPS | -171.43% | 255.56% | |||
| Average Basic Shares Outstanding | 6.85% | 69.54% | |||
| Average Diluted Shares Outstanding | 6.85% | 69.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||